GYRE Rasio cepet Gyre Therapeutics, Inc.

Simbol resmi perusahaan Gyre Therapeutics (GYRE)

Gyre Therapeutics, Inc. (GYRE) holds exclusive rights to an anti-fibrotic agent in the PRC, supported by patent protection and government backing. The business relies on close collaboration with scientific centers to accelerate therapies for lung and liver diseases. Market price visualization on GURU.Markets shows a value of 3.80, as the company scales the rollout of Hydronidone in China and funds US trials for global market capture.

GYRE: Rasio jangkoan perantara Gyre Corp 21.02.2024 - 31.10.2026

Ringkesan rincian data analitis gyretx.com (GYRE)

- nilai pasar lan prakiraan target analis:
Bagan rega Gyre Corp|GYRE - Target konsensus
- data kapitalisasi pasar:
Kapitalisasi pasar Gyre Corp|GYRE - Nilai Perusahaan
- indikator nilai aset resik miturut neraca:
Nilai Akuntansi saben Saham Gyre Therapeutics|GYRE - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku gyretx.com|GYRE - Aset Agregat Perusahaan
- data utang lan likuiditas:
Total Utang marang Modal Gyre Therapeutics, Inc.|GYRE - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Gyre Therapeutics|GYRE - Utang perusahaan|Utang-utang marang kapitalisasi buku Gyre Corp|GYRE - Utang jangka dawa|Utang jangka cendhak perusahaan Gyre Therapeutics|Rasio cepet gyretx.com
- informasi bathi lan kelipatan valuasi:
GYRE - Bathi resik taunan
Pambiji fundamental:Gyre Corp - GYRE
Barang unggulan Gyre Therapeutics Inc

The specifics of the biotechnology sector demand colossal expenditures on clinical trials, where the risk of failure is high. Analyzing the quick ratio chart, an investor can see the ability of Gyre Therapeutics, Inc. (GYRE) to cover short-term obligations solely through cash and accounts receivable, excluding illiquid inventories. The stability of this metric confirms the company's financial resilience in the face of fierce competition from pharma behemoths.

Analisis perusahaan pesaing

Arrowhead Pharmaceuticals Inc (ARWR) - Likuiditas cepet|Indikator likuiditas cepet Mirum Pharmaceuticals Inc|DVAX (Dynavax Technologies Corp) - Rasio cepet|Rasio cepet arbutusbio.com|Indikator likuiditas cepet IVA (Inventiva)|ASMB (Assembly Bio) - Rasio jangkoan perantara|Likuiditas cepet Galectin Therapeutics Inc. GALT|Genfit SA - Likuiditas cepet|DURECT Corp. - Rasio cepet|Koefisien jangkoan perantara Aligos Therapeutics ALGS|BIVI (biovieinc.com) - Indikator likuiditas cepet|GLMD (Galmed Pharmaceuticals Ltd.) - Likuiditas cepet|NDRA (ENDRA) - Rasio cepet|Likuiditas darurat Hepion Pharma HEPA